• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Intraday Session

    5/30/24 12:31:20 PM ET
    $BSGM
    $DARE
    $HLTH
    $ISPC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BSGM alert in real time by email

    Gainers

    • Cue Health (NASDAQ:HLTH) shares rose 70.1% to $0.09 during Thursday's regular session. The market value of their outstanding shares is at $14.8 million.
    • OneMedNet (NASDAQ:ONMD) shares increased by 29.23% to $2.52. The company's market cap stands at $60.1 million.
    • iSpecimen (NASDAQ:ISPC) shares moved upwards by 22.87% to $0.39. The company's market cap stands at $3.8 million.
    • Xeris Biopharma Holdings (NASDAQ:XERS) shares increased by 18.13% to $2.28. The market value of their outstanding shares is at $338.0 million.
    • Kintara Therapeutics (NASDAQ:KTRA) stock rose 18.01% to $0.32. The market value of their outstanding shares is at $17.7 million.
    • Lexaria Bioscience (NASDAQ:LEXX) shares increased by 14.47% to $4.35. The market value of their outstanding shares is at $68.7 million.

    Losers

    • Sonoma Pharmaceuticals (NASDAQ:SNOA) shares fell 17.1% to $0.22 during Thursday's regular session. The company's market cap stands at $3.3 million.
    • BioSig Technologies (NASDAQ:BSGM) stock declined by 15.02% to $2.04. The company's market cap stands at $25.4 million.
    • Mira Pharmaceuticals (NASDAQ:MIRA) shares fell 11.25% to $0.78. The company's market cap stands at $11.5 million.
    • Innovative Eyewear (NASDAQ:LUCY) shares declined by 10.95% to $0.85. The company's market cap stands at $14.7 million.
    • Reshape Lifesciences (NASDAQ:RSLS) stock declined by 10.68% to $0.25. The market value of their outstanding shares is at $5.8 million.
    • Dare Bioscience (NASDAQ:DARE) stock decreased by 10.6% to $0.42. The market value of their outstanding shares is at $42.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BSGM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BSGM
    $DARE
    $HLTH
    $ISPC

    CompanyDatePrice TargetRatingAnalyst
    Xeris Biopharma Holdings Inc.
    $XERS
    12/9/2025$9.00Overweight
    Barclays
    Xeris Biopharma Holdings Inc.
    $XERS
    8/12/2025$10.00Buy
    H.C. Wainwright
    Xeris Biopharma Holdings Inc.
    $XERS
    11/11/2024$3.00Overweight → Neutral
    Piper Sandler
    Xeris Biopharma Holdings Inc.
    $XERS
    3/28/2024$5.00Outperform
    Oppenheimer
    Cue Health Inc.
    $HLTH
    3/14/2024Buy → Neutral
    BTIG Research
    Xeris Biopharma Holdings Inc.
    $XERS
    8/28/2023$4.50Buy
    Craig Hallum
    Xeris Biopharma Holdings Inc.
    $XERS
    10/21/2022$4.00Buy
    Jefferies
    Xeris Biopharma Holdings Inc.
    $XERS
    4/28/2022$6.50Buy
    Craig Hallum
    More analyst ratings

    $BSGM
    $DARE
    $HLTH
    $ISPC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance

    Achieved record quarterly and full-year total revenue of $86 million and $292 million, respectively Provides full year 2026 total revenue guidance range of $375 million to $390 million Hosts conference call and webcast today at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provides financial guidance for full year 2026. "Thanks to the entire Xeris organization, 2025 was a transformational year, marked by focused e

    3/2/26 7:00:00 AM ET
    $XERS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OneMedNet Announces Next Phase of Commercial Launch with its Real-World Data (RWD) Platform powered by Palantir Foundry

    MINNEAPOLIS, Feb. 27, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) (the "OneMedNet," the "Company," "we," "us" or "our"), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced the next phase of commercial launch with its RWD Platform powered by Palantir Foundry. Following the successful November 10, 2025, demonstration of live feeds, subscription access, and AI-driven search at major tradeshows, the Company is actively converting customer evaluations into commercial subscriptions. Early results highlight superior performance, speed and analytical depth, reinforcing OneMedNet's position for life sciences and healthcare organizations generati

    2/27/26 8:50:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit

    Four Orange Book Listed Patents through March 2040 Orphan Drug Exclusivity through December 2028 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, announced that its subsidiaries, Xeris Pharmaceuticals, Inc. and Strongbridge Dublin Limited, have filed a patent infringement lawsuit under the Hatch-Waxman Act related to Recorlev® (levoketoconazole) in the United States District Court for the District of New Jersey against Torrent Pharmaceuticals Limited (along with its affiliate) and Somerset Therapeutics, LLC (along with its affiliat

    2/26/26 5:55:00 PM ET
    $XERS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BSGM
    $DARE
    $HLTH
    $ISPC
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 6, 2023 - FDA Permits Marketing of First COVID-19 At-Home Test Using Traditional Premarket Review Process

    For Immediate Release: June 06, 2023 Today, the U.S. Food and Drug Administration granted marketing authorization for the Cue COVID-19 Molecular Test. The product is a molecular nucleic acid amplification test (NAAT) that is intended to detect genetic material from SARS-CoV-2 virus present in nasal swabs from adults with signs and symptoms of upper respiratory infection. This test is the first at-home over-the-c

    6/6/23 3:04:14 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    FDA Approval for XACIATO issued to DARE BIOSCIENCE INC

    Submission status for DARE BIOSCIENCE INC's drug XACIATO (ORIG-1) with active ingredient CLINDAMYCIN PHOSPHATE has changed to 'Approval' on 12/07/2021. Application Category: NDA, Application Number: 215650, Application Classification: Type 5 - New Formulation or New Manufacturer

    12/7/21 12:35:25 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BSGM
    $DARE
    $HLTH
    $ISPC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $BSGM
    $DARE
    $HLTH
    $ISPC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $BSGM
    $DARE
    $HLTH
    $ISPC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Officer Hecht Beth sold $104,086 worth of shares (16,667 units at $6.25), decreasing direct ownership by 1% to 1,226,507 units (SEC Form 4)

    4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)

    3/4/26 5:28:47 PM ET
    $XERS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Nguyen Anh Tu covered exercise/tax liability with 29,300 shares, decreasing direct ownership by 7% to 395,023 units (SEC Form 4)

    4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)

    2/25/26 6:03:14 PM ET
    $XERS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chef Executive Officer Johnson Sabrina Martucci

    4 - Dare Bioscience, Inc. (0001401914) (Issuer)

    2/20/26 4:01:50 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Gross Harrison R. bought $1,980 worth of shares (1,500 units at $1.32), increasing direct ownership by 12% to 13,733 units (SEC Form 4)

    4 - Innovative Eyewear Inc (0001808377) (Issuer)

    1/22/26 11:29:05 AM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Chief Financial Officer Gayle Oswald bought $1,669 worth of shares (1,000 units at $1.67), increasing direct ownership by 54% to 2,865 units (SEC Form 4)

    4 - Innovative Eyewear Inc (0001808377) (Issuer)

    1/15/26 5:00:07 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Chief Executive Officer Gross Harrison R. bought $2,400 worth of shares (1,500 units at $1.60), increasing direct ownership by 14% to 12,233 units (SEC Form 4)

    4 - Innovative Eyewear Inc (0001808377) (Issuer)

    1/12/26 5:00:39 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Barclays initiated coverage on Xeris Biopharma with a new price target

    Barclays initiated coverage of Xeris Biopharma with a rating of Overweight and set a new price target of $9.00

    12/9/25 8:55:16 AM ET
    $XERS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on Xeris Biopharma with a new price target

    H.C. Wainwright resumed coverage of Xeris Biopharma with a rating of Buy and set a new price target of $10.00

    8/12/25 8:02:13 AM ET
    $XERS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xeris Biopharma downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Xeris Biopharma from Overweight to Neutral and set a new price target of $3.00

    11/11/24 7:52:12 AM ET
    $XERS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BSGM
    $DARE
    $HLTH
    $ISPC
    SEC Filings

    View All

    SEC Form DEFA14A filed by iSpecimen Inc.

    DEFA14A - iSpecimen Inc. (0001558569) (Filer)

    3/3/26 4:05:22 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    MIRA Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

    8-K - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)

    3/3/26 4:01:24 PM ET
    $MIRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Xeris Biopharma Holdings Inc.

    144 - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)

    3/2/26 4:36:21 PM ET
    $XERS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BSGM
    $DARE
    $HLTH
    $ISPC
    Financials

    Live finance-specific insights

    View All

    Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance

    Achieved record quarterly and full-year total revenue of $86 million and $292 million, respectively Provides full year 2026 total revenue guidance range of $375 million to $390 million Hosts conference call and webcast today at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provides financial guidance for full year 2026. "Thanks to the entire Xeris organization, 2025 was a transformational year, marked by focused e

    3/2/26 7:00:00 AM ET
    $XERS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026

    Conference Call to be Held at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its fourth quarter and full year 2025 financial results before the open of the U.S. financial markets on Monday, March 2, 2026. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company's financial and operational results. To pre-register for the call, please go to the following link: https://events.q4inc.com/analyst/428274643?pwd=TZMrH35H Afte

    2/17/26 7:30:00 AM ET
    $XERS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OneMedNet Reports 815% Bookings Increase and 4.5X increase in Inbound Demand

    MINNEAPOLIS, Nov. 17, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) ("OneMedNet," the "Company," "we," "us" or "our"), a leader in AI-powered Real-World Data (RWD), announced its financial results for the third quarter ended September 30, 2025 and operational highlights. Third Quarter Financial Highlights Bookings:  $1.1M in third quarter 2025 bookings, an 815% increase compared to third quarter of 2024.Private Placements: Successfully completed an additional $0.5M private placement of common stock from an insider, providing further investment towards strategic objectives.Further Improved Balance Sheet: Continuing with its efforts first reported at the end of the second qu

    11/17/25 7:45:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $BSGM
    $DARE
    $HLTH
    $ISPC
    Leadership Updates

    Live Leadership Updates

    View All

    Vyome Announces New Board of Directors with Deep MIT and AI Ties

    Heavily shareholder-aligned board and management team completely replaces ReShape team as Vyome prepares for public listing on August 15, 2025 Vyome Therapeutics, Inc., a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, today announced its post-closing Board of Directors, expected to take control of the ReShape Lifesciences (NASDAQ:RSLS) public entity on Friday, August 15, 2025, which will be renamed Vyome Holdings, Inc. post-closing and trade under the ticker symbol HIND. The new Vyome board members, which include four Massachusetts Institute of Technology (MIT) alums, are all persons with prior

    8/12/25 9:48:00 AM ET
    $RSLS
    Medical/Dental Instruments
    Health Care

    Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream

    A first-of-its-kind solution for women's arousal in a proprietary topical formulation demonstrated to work where women need it most Targeted to be available by prescription in the fourth quarter of 2025 Collaboration leverages Rosy Wellness' extensive reach and community of over 250,000 women; campaign designed to drive awareness and support women with arousal concerns SAN DIEGO, July 29, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a biopharmaceutical company with a sole focus of closing the gap in women's health between promising science and real solutions, and Rosy Wellness, a pioneering digital platform focused on providing lifespan support for women, today announce

    7/29/25 8:00:00 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioSig & Streamex Appoint Defi Expert and Visionary, Russell Starr as Strategic Advisor

    BioSig Technologies, Inc. ("BioSig" or the "Company"), which recently merged with Streamex Exchange Corporation ("Streamex") (NASDAQ:BSGM), is pleased to announce the appointment of Russell Starr as Strategic Advisor to Streamex. Mr. Starr brings decades of experience in capital markets, business development, and transformative deal-making across, defi, traditional finance and emerging sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250711280588/en/ A former executive on Bay Street and respected entrepreneur and financier, Mr. Starr has built a reputation for navigating high-stakes financial transactions and guiding comp

    7/11/25 9:00:00 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BSGM
    $DARE
    $HLTH
    $ISPC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Lexaria Bioscience Corp.

    SC 13G/A - Lexaria Bioscience Corp. (0001348362) (Subject)

    11/14/24 4:11:11 PM ET
    $LEXX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by BioSig Technologies Inc.

    SC 13G/A - BioSig Technologies, Inc. (0001530766) (Subject)

    11/14/24 3:58:00 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Innovative Eyewear Inc.

    SC 13G/A - Innovative Eyewear Inc (0001808377) (Subject)

    11/13/24 11:18:48 AM ET
    $LUCY
    Ophthalmic Goods
    Health Care